| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 40 | 2025 | 1231 | 9.990 |
Why?
|
| Primary Health Care | 23 | 2025 | 379 | 6.440 |
Why?
|
| Diabetes Mellitus | 20 | 2025 | 767 | 4.040 |
Why?
|
| Hypoglycemic Agents | 16 | 2025 | 379 | 3.470 |
Why?
|
| Patient Portals | 4 | 2025 | 23 | 3.360 |
Why?
|
| Mass Screening | 9 | 2025 | 711 | 3.150 |
Why?
|
| Depression | 10 | 2025 | 544 | 3.000 |
Why?
|
| Psychiatry | 4 | 2023 | 88 | 2.780 |
Why?
|
| Blood Glucose | 14 | 2024 | 868 | 2.650 |
Why?
|
| Diabetes Complications | 12 | 2024 | 170 | 2.160 |
Why?
|
| Physicians | 7 | 2022 | 683 | 2.040 |
Why?
|
| Hypothyroidism | 6 | 2026 | 275 | 2.020 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2025 | 122 | 1.810 |
Why?
|
| Physicians, Primary Care | 3 | 2025 | 110 | 1.780 |
Why?
|
| Qualitative Research | 4 | 2025 | 348 | 1.780 |
Why?
|
| Humans | 114 | 2026 | 93615 | 1.710 |
Why?
|
| Aging | 11 | 2025 | 727 | 1.710 |
Why?
|
| Medicaid | 7 | 2022 | 259 | 1.450 |
Why?
|
| HIV Infections | 3 | 2025 | 961 | 1.380 |
Why?
|
| Mental Health Services | 3 | 2024 | 77 | 1.360 |
Why?
|
| Cost Sharing | 4 | 2024 | 20 | 1.320 |
Why?
|
| Thyrotropin | 5 | 2026 | 309 | 1.290 |
Why?
|
| Cardiovascular Diseases | 8 | 2026 | 755 | 1.290 |
Why?
|
| United States | 28 | 2025 | 7645 | 1.290 |
Why?
|
| Thyroxine | 6 | 2026 | 386 | 1.250 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2024 | 64 | 1.240 |
Why?
|
| Chronic Pain | 4 | 2025 | 187 | 1.140 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 441 | 1.130 |
Why?
|
| Male | 55 | 2026 | 44578 | 1.120 |
Why?
|
| Interviews as Topic | 4 | 2025 | 364 | 1.120 |
Why?
|
| Female | 57 | 2026 | 48779 | 1.120 |
Why?
|
| Adult | 33 | 2026 | 27955 | 1.080 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 582 | 1.060 |
Why?
|
| Nutrition Surveys | 7 | 2023 | 125 | 1.060 |
Why?
|
| Aged | 42 | 2026 | 20469 | 1.030 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 64 | 1.020 |
Why?
|
| Documentation | 3 | 2022 | 97 | 1.020 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 171 | 1.010 |
Why?
|
| Electronic Health Records | 4 | 2025 | 374 | 1.000 |
Why?
|
| Middle Aged | 38 | 2026 | 27621 | 0.990 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 496 | 0.980 |
Why?
|
| Pain Management | 2 | 2025 | 180 | 0.970 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 660 | 0.880 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 30 | 0.880 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 1866 | 0.860 |
Why?
|
| Cost-Benefit Analysis | 10 | 2025 | 494 | 0.810 |
Why?
|
| Chronic Disease | 4 | 2022 | 962 | 0.790 |
Why?
|
| Hormone Replacement Therapy | 3 | 2024 | 93 | 0.780 |
Why?
|
| Health Expenditures | 1 | 2024 | 102 | 0.770 |
Why?
|
| Anti-HIV Agents | 1 | 2025 | 195 | 0.750 |
Why?
|
| Quality-Adjusted Life Years | 8 | 2025 | 157 | 0.750 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.740 |
Why?
|
| Anxiety | 2 | 2024 | 338 | 0.740 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.730 |
Why?
|
| Metformin | 2 | 2024 | 125 | 0.730 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 76 | 0.720 |
Why?
|
| Systems Integration | 2 | 2021 | 33 | 0.710 |
Why?
|
| Outpatients | 1 | 2022 | 105 | 0.700 |
Why?
|
| Schools, Medical | 1 | 2023 | 132 | 0.700 |
Why?
|
| Hospitalization | 3 | 2021 | 938 | 0.690 |
Why?
|
| Obesity | 4 | 2025 | 1019 | 0.680 |
Why?
|
| Referral and Consultation | 1 | 2024 | 376 | 0.670 |
Why?
|
| Quality of Life | 7 | 2021 | 1783 | 0.670 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 490 | 0.670 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 256 | 0.660 |
Why?
|
| Thyroid Hormones | 2 | 2023 | 350 | 0.650 |
Why?
|
| Patient Preference | 2 | 2025 | 125 | 0.650 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.640 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 25 | 0.630 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 233 | 0.620 |
Why?
|
| Breast Density | 1 | 2020 | 42 | 0.610 |
Why?
|
| State Health Plans | 1 | 2019 | 13 | 0.600 |
Why?
|
| Program Evaluation | 1 | 2020 | 315 | 0.580 |
Why?
|
| Hypertension | 3 | 2016 | 758 | 0.580 |
Why?
|
| Opioid-Related Disorders | 4 | 2024 | 233 | 0.580 |
Why?
|
| Quality of Health Care | 3 | 2022 | 383 | 0.570 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 19 | 0.560 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 419 | 0.550 |
Why?
|
| Follow-Up Studies | 8 | 2026 | 3835 | 0.550 |
Why?
|
| Veterans | 1 | 2019 | 100 | 0.550 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 291 | 0.540 |
Why?
|
| Community Health Centers | 2 | 2022 | 119 | 0.540 |
Why?
|
| Medicare | 4 | 2024 | 455 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 589 | 0.510 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 453 | 0.500 |
Why?
|
| Public Health | 2 | 2021 | 154 | 0.500 |
Why?
|
| Communication | 1 | 2020 | 435 | 0.490 |
Why?
|
| Risk Assessment | 6 | 2025 | 2444 | 0.490 |
Why?
|
| Quality Improvement | 2 | 2017 | 485 | 0.480 |
Why?
|
| Health Policy | 2 | 2016 | 207 | 0.480 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 4 | 0.480 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 337 | 0.480 |
Why?
|
| Surveys and Questionnaires | 10 | 2025 | 2806 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 333 | 0.460 |
Why?
|
| Medication Adherence | 1 | 2016 | 122 | 0.450 |
Why?
|
| Attitude to Health | 1 | 2016 | 217 | 0.450 |
Why?
|
| Glucose | 3 | 2022 | 692 | 0.440 |
Why?
|
| Insurance Coverage | 2 | 2019 | 144 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1056 | 0.420 |
Why?
|
| Leadership | 2 | 2017 | 149 | 0.410 |
Why?
|
| Preventive Health Services | 1 | 2014 | 38 | 0.410 |
Why?
|
| Health Care Reform | 2 | 2015 | 83 | 0.400 |
Why?
|
| Urban Population | 2 | 2025 | 234 | 0.400 |
Why?
|
| Longitudinal Studies | 5 | 2026 | 1165 | 0.390 |
Why?
|
| Analgesics, Opioid | 5 | 2025 | 513 | 0.380 |
Why?
|
| Coronary Disease | 1 | 2014 | 223 | 0.380 |
Why?
|
| Chicago | 3 | 2025 | 1464 | 0.380 |
Why?
|
| Academic Medical Centers | 4 | 2025 | 397 | 0.370 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 208 | 0.370 |
Why?
|
| Disease Progression | 4 | 2024 | 1531 | 0.360 |
Why?
|
| Comorbidity | 5 | 2018 | 1007 | 0.350 |
Why?
|
| Informed Consent | 2 | 2023 | 277 | 0.330 |
Why?
|
| Young Adult | 8 | 2025 | 6938 | 0.330 |
Why?
|
| Sodium | 2 | 2022 | 329 | 0.330 |
Why?
|
| Models, Economic | 3 | 2024 | 62 | 0.330 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 117 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 920 | 0.320 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 185 | 0.310 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2024 | 62 | 0.310 |
Why?
|
| Risk Factors | 7 | 2025 | 5912 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 225 | 0.300 |
Why?
|
| Insulin | 3 | 2024 | 1185 | 0.290 |
Why?
|
| Markov Chains | 2 | 2020 | 136 | 0.290 |
Why?
|
| Prospective Studies | 7 | 2024 | 4565 | 0.280 |
Why?
|
| Time Factors | 5 | 2026 | 5406 | 0.280 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 192 | 0.280 |
Why?
|
| Hypoglycemia | 2 | 2024 | 113 | 0.280 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 7073 | 0.270 |
Why?
|
| Life Expectancy | 3 | 2023 | 91 | 0.270 |
Why?
|
| Adolescent | 5 | 2025 | 9610 | 0.260 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 72 | 0.250 |
Why?
|
| California | 5 | 2025 | 158 | 0.250 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2718 | 0.250 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2025 | 59 | 0.240 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 58 | 0.240 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2025 | 15 | 0.220 |
Why?
|
| Medicare Part D | 1 | 2025 | 12 | 0.220 |
Why?
|
| Job Satisfaction | 2 | 2018 | 80 | 0.220 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 16 | 0.220 |
Why?
|
| Anti-Obesity Agents | 1 | 2025 | 16 | 0.220 |
Why?
|
| Physician Assistants | 1 | 2025 | 26 | 0.220 |
Why?
|
| Costs and Cost Analysis | 3 | 2020 | 154 | 0.220 |
Why?
|
| Deprescriptions | 1 | 2025 | 10 | 0.220 |
Why?
|
| Prognosis | 3 | 2026 | 3913 | 0.220 |
Why?
|
| Health Care Surveys | 2 | 2019 | 286 | 0.220 |
Why?
|
| Viral Load | 1 | 2025 | 154 | 0.220 |
Why?
|
| Internship and Residency | 2 | 2011 | 1092 | 0.210 |
Why?
|
| Triiodothyronine | 2 | 2023 | 361 | 0.210 |
Why?
|
| Colorado | 1 | 2024 | 39 | 0.210 |
Why?
|
| Health Care Costs | 3 | 2024 | 252 | 0.210 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 577 | 0.210 |
Why?
|
| Self-Management | 1 | 2024 | 44 | 0.210 |
Why?
|
| Retrospective Studies | 6 | 2024 | 10186 | 0.210 |
Why?
|
| Osteoporotic Fractures | 1 | 2025 | 53 | 0.210 |
Why?
|
| Efficiency | 2 | 2021 | 39 | 0.200 |
Why?
|
| Geriatrics | 1 | 2024 | 66 | 0.200 |
Why?
|
| Education, Medical, Continuing | 1 | 2024 | 102 | 0.200 |
Why?
|
| Bone Density | 1 | 2025 | 237 | 0.200 |
Why?
|
| Fractures, Bone | 1 | 2025 | 155 | 0.200 |
Why?
|
| Logistic Models | 2 | 2019 | 1246 | 0.190 |
Why?
|
| Parental Leave | 1 | 2023 | 4 | 0.190 |
Why?
|
| Prevalence | 2 | 2019 | 1322 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 108 | 0.190 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 36 | 0.190 |
Why?
|
| Insurance, Health | 2 | 2015 | 180 | 0.190 |
Why?
|
| Organizational Policy | 1 | 2023 | 57 | 0.180 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 30 | 0.180 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 146 | 0.180 |
Why?
|
| Suicide | 1 | 2024 | 164 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2025 | 9108 | 0.180 |
Why?
|
| Buprenorphine | 1 | 2022 | 52 | 0.180 |
Why?
|
| Waiting Lists | 1 | 2023 | 211 | 0.170 |
Why?
|
| Dementia | 1 | 2023 | 214 | 0.170 |
Why?
|
| Pediatrics | 1 | 2025 | 386 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2020 | 917 | 0.160 |
Why?
|
| Computers | 1 | 2020 | 102 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 875 | 0.160 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 48 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.150 |
Why?
|
| Emotions | 1 | 2023 | 372 | 0.150 |
Why?
|
| Curriculum | 1 | 2024 | 594 | 0.150 |
Why?
|
| Fasting | 1 | 2020 | 164 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 330 | 0.150 |
Why?
|
| Blood Pressure | 2 | 2015 | 896 | 0.150 |
Why?
|
| Internal Medicine | 4 | 2021 | 336 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2019 | 121 | 0.140 |
Why?
|
| Demography | 2 | 2023 | 190 | 0.140 |
Why?
|
| Length of Stay | 1 | 2022 | 828 | 0.140 |
Why?
|
| United Kingdom | 2 | 2024 | 190 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 20 | 0.140 |
Why?
|
| Work Engagement | 1 | 2017 | 6 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2023 | 3061 | 0.130 |
Why?
|
| Inservice Training | 1 | 2017 | 36 | 0.130 |
Why?
|
| Poverty | 1 | 2019 | 193 | 0.130 |
Why?
|
| Patient Participation | 1 | 2019 | 230 | 0.130 |
Why?
|
| Urban Health Services | 1 | 2017 | 46 | 0.130 |
Why?
|
| Cost Savings | 1 | 2017 | 68 | 0.130 |
Why?
|
| Health Status Disparities | 2 | 2023 | 219 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 388 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 503 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2016 | 19 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 179 | 0.120 |
Why?
|
| Financing, Personal | 1 | 2016 | 21 | 0.120 |
Why?
|
| Linear Models | 2 | 2018 | 414 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 87 | 0.120 |
Why?
|
| Overweight | 1 | 2017 | 120 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2016 | 45 | 0.120 |
Why?
|
| Medical Overuse | 1 | 2016 | 30 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 836 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 119 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 250 | 0.120 |
Why?
|
| Life Style | 1 | 2016 | 183 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1918 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2018 | 1525 | 0.110 |
Why?
|
| Phenotype | 1 | 2021 | 2543 | 0.110 |
Why?
|
| Data Accuracy | 1 | 2015 | 32 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 485 | 0.110 |
Why?
|
| Federal Government | 1 | 2014 | 28 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 228 | 0.100 |
Why?
|
| Health Surveys | 2 | 2013 | 245 | 0.100 |
Why?
|
| Medically Uninsured | 1 | 2014 | 67 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2018 | 1119 | 0.100 |
Why?
|
| Child | 1 | 2025 | 7359 | 0.100 |
Why?
|
| Primary Prevention | 2 | 2013 | 86 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2015 | 333 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 246 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 356 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 11 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 713 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2017 | 812 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 281 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 69 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 41 | 0.080 |
Why?
|
| Registries | 2 | 2013 | 996 | 0.080 |
Why?
|
| Burnout, Professional | 1 | 2013 | 113 | 0.080 |
Why?
|
| Health Status | 2 | 2023 | 377 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 175 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 224 | 0.070 |
Why?
|
| Disease Management | 1 | 2011 | 359 | 0.070 |
Why?
|
| Counseling | 1 | 2009 | 168 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1923 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1079 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 381 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2025 | 51 | 0.050 |
Why?
|
| Brazil | 1 | 2024 | 81 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 13 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2024 | 20 | 0.050 |
Why?
|
| Calibration | 1 | 2024 | 107 | 0.050 |
Why?
|
| Drug Costs | 1 | 2025 | 66 | 0.050 |
Why?
|
| Insulin Glargine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 1954 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2023 | 123 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 6 | 0.050 |
Why?
|
| Dronabinol | 1 | 2023 | 58 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 19 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 155 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 56 | 0.050 |
Why?
|
| Methadone | 1 | 2022 | 51 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2021 | 16 | 0.040 |
Why?
|
| Naltrexone | 1 | 2022 | 139 | 0.040 |
Why?
|
| Jurisprudence | 1 | 2021 | 24 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 402 | 0.040 |
Why?
|
| Community Networks | 1 | 2021 | 32 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 520 | 0.040 |
Why?
|
| Survival Rate | 2 | 2014 | 1950 | 0.040 |
Why?
|
| Social Stigma | 1 | 2019 | 88 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2024 | 822 | 0.040 |
Why?
|
| Economics, Medical | 1 | 2018 | 6 | 0.030 |
Why?
|
| Motivation | 1 | 2021 | 310 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 189 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 1912 | 0.030 |
Why?
|
| Checklist | 1 | 2018 | 73 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 624 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 123 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 159 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 28041 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 234 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 22 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 47 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 55 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 620 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 629 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1723 | 0.020 |
Why?
|
| Clinical Audit | 1 | 2013 | 9 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 884 | 0.020 |
Why?
|
| New York City | 1 | 2013 | 69 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2013 | 90 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 28 | 0.020 |
Why?
|
| Family Practice | 1 | 2013 | 73 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 990 | 0.020 |
Why?
|
| Medical Errors | 1 | 2013 | 94 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 174 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 206 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2375 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 238 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1702 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1907 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 370 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2009 | 337 | 0.020 |
Why?
|